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Abstract
Phenanthridine derivatives are one of the most intensively studied families of biologically active compounds with efficient DNA
binding capability. Attracting attention since DNA structure discovery (1960s), they were early recognized as a symbol of DNA
intercalative binding, for many decades applied as gold-standard DNA- and RNA-fluorescent markers (ethidium bromide), probes
for cell viability (propidium iodide), but also “ill-famed” for various toxic (genotoxic) and mutagenic effects. After two decades of
low interest, the discovery of phenanthridine alkaloids and new studies of antiparasitic/antitumor properties of phenanthridine
derivatives resulted in the strong increase of the scientific interest about the turn of this century. Here are summarized phenanthri-
dine-related advances in the 21st century (2000-present period) with emphasis on the supramolecular interactions and bioorganic
chemistry, as well as novel or improved synthetic approaches.
Introduction
The search for therapeutic agents of the phenanthridine type has
increased when the outstanding trypanocidal activity of some
phenanthridinium compounds became apparent [1]. One of the
most studied and used phenanthridine derivatives is 3,8-
diamino-5-ethyl-6-phenylphenanthridinium known as ethidium
bromide (EB), for many decades applied as gold-standard
DNA- and RNA-fluorescent marker, and its close analogue
(propidium iodide) as a probe for cell viability. Besides, an
antiparasitic activity for EB was reported and it possesses
significant antitumor activity [2-5] both in vivo and in vitro.
Nevertheless, phenanthridine derivatives were rather neglected
regarding their human medicinal applications due to potential
carcinogenic and mutagenic properties of some derivatives (EB
and analogues), which had negative influence on biomedically-
oriented studies of the complete phenanthridine class till the end
of the 20th century.
However, discovery of phenanthridine alkaloid analogues and
in parallel new studies of antiparasitic properties of phenanthri-
dine derivatives resulted in a strong increase of the scientific
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Scheme 2: Radical-mediated synthesis of 6-arylphenanthridine [14].
interest about the turn of this century, consequently yielding
many publications at high impact chemical and biomedicinal
journals, and patents covering various chemical, biochemical
and biomedical uses. These results are up to our knowledge not
summarized in any review within the last 10 years. Thus, taking
advantage of our 20-year experience on phenanthridine deriva-
tives (including very scarcely studied 4,9-diazapyrenium
analogues with highly interesting biological effects), we
summarized literature data (advances from 2000 to present)
concerning supramolecular, bioorganic and medicinal chem-
istry, as well as novel or improved synthetic approaches.
Review
How to get phenanthridine: advances in
synthetic pathways
Phenanthridine was first synthesized at the end of 19th century
by Pictet and Ankersmit through pyrolysis of the condensation
product of benzaldehyde and aniline [6]. The reaction condi-
tions were improved by Morgan and Walls, based on a reaction
including a cyclization of phenanthridine by dehydrative ring-
closure with phosphorus oxychloride in boiling nitrobenzene
[7]. Over the 20th century this method of phenanthridine
preparation became the most common one. However, increased
interest over the last decades resulted in many new and substan-
tially different ways of phenanthridine synthesis with several
different goals: to improve the reaction yield and to equip the
phenanthridine moiety with various substituents, which were
nicely summarized by Keller a decade ago [8]. We tried to
survey the wide range of synthetic methods applied from 2000
on organizing them by similarity of reactants/catalysts or
organic reactions; for instance the anionic ring-closure reac-
tions using Grignard reagents (Scheme 1) [9], Bischler–Napier-
alski reactions [10], reduction of phenanthridones [11,12], free
radical methodology, palladium/rhodium/iron-catalysed reac-
tions, etc.
One of the approaches to the large variety of 6-arylphenanthri-
dine derivatives was the synthesis starting from benzotriazole
derivatives of diarylmethanes, acridine, xanthene, thioxanthene,
etc. It was based on the generation of a benzotriazole-stabilized
Scheme 1: The Grignard-based synthesis of 6-alkyl phenanthridine.
carbanion followed by oxidation of this carbanion by copper
iodide to form a radical. Subsequent elimination of nitrogen fol-
lowed by ring closure yielded phenanthridine (Scheme 2)
[13,14].
In the 1980s, Leardini et al. [15] have shown that under radical
conditions via a homolytic aromatic substitution route diaryl-
imines were suitable precursors to a number of 6-arylphenan-
thridine derivatives. The reaction proceeded by initial imidoyl-
H atom abstraction by the electrophilic iPrO• radical, and subse-
quently the intermediate underwent intramolecular cyclization
and oxidative aromatization to form the phenanthridine ring.
Bowman et al. [16] modified this route for safety reasons by
application of di(tert-butyl)peroxide as a source of the t-BuO•
radical (Scheme 3). The required arylimines were prepared
from aminobiphenyl and arylaldehyde in dichloromethane in
the presence of molecular sieves at room temperature. Radical
cyclisation in the presence of (tert-butyl)peroxide in chloroben-
zene at 140–150 °C for 48 h, yielded the corresponding phenan-
thridines in moderate yields. The t-BuO• radical eliminated the
imine-H and formed the imidoyl radical, added to the phenyl
ring. The homolytic aromatic substitution was terminated by
H-atom abstraction by another t-BuO• radical.
Among very few routes targeting the synthesis of 5,6-unsubsti-
tuted phenanthridines, the here presented radical-based pathway
used readily available N-(o-halobenzyl)arylamines as starting
materials [17]. The o-haloarylbenzylamines (obtained by
nucleophilic substitution of various anilines with 2-iodobenzyl
chloride) gave the corresponding amide anions by an SRN1
substitution reaction in NH3 or DMSO as solvent under
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Scheme 4: Synthesis of 5,6-unsubstituted phenanthridine starting from 2-iodobenzyl chloride and aniline [17].
Scheme 5: Phenanthridine synthesis initiated by UV-light irradiation photolysis of acetophenone O-ethoxycarbonyloxime derivatives at room tempera-
ture [18].
Scheme 3: A t-BuO• radical-assisted homolytic aromatic substitution
mechanism proposed for the conversion of diarylimine into the
6-arylphenanthridine derivatives [16].
photoinitiation in the presence of excess t-BuOK. The photoin-
duced ET to the amide-anion resulted in its radical anion. After
fragmentation of the C–I bond, an intramolecular cyclization
occurred, and after acidification of the reaction medium, the
oxidized phenanthridine compounds were obtained in very good
yields (up to 95%, Scheme 4).
McBurney et al. prepared various N-heterocycles, using oxime
carbonates as excellent precursors for the photoinduced genera-
tion of iminyl radicals, whereby at standard photolysis condi-
tions, 3-substituted 6-methylphenanthridines were obtained in
good to quantitative yields (52–99%, Scheme 5). Important
advantages of the method are environmentally friendly and
easily removable byproducts (CO2 and ethanol or phenol), and
the negligible impact of the electronic nature of the substituent
on the reaction [18].
The oxidative PhI(OAc)2-mediated cyclization of 2-isocyanobi-
phenyls with CF3SiMe3 under metal-free conditions showed to
be a mild and efficient approach to 6-(trifluoromethyl)phenan-
thridines, characterised by good yields with high regioselec-
tivity at ambient temperature (Scheme 6) [19,20].
Another radical-based route (targeting 6-perfluoroalkylphenan-
thridines), in which the transition metal is omitted, relied on the
trifluoromethylation of isonitriles to yield trifluoromethylphen-
anthridines (Scheme 7) [21]. This approach employed the Togni
reagent, and Bu4NI was applied as radical initiator; whereby
phenanthridines were prepared in good to excellent yields [22].
Starting from the similar isonitrile structure, 6-aroylated
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Scheme 6: PhI(OAc)2-mediated oxidative cyclization of 2-isocyanobiphenyls with CF3SiMe3 [19,20].
Scheme 7: Targeting 6-perfluoroalkylphenanthridines [21,22].
phenanthridines via base promoted homolytic aromatic substitu-
tion (BHAS) can be prepared [23].
Several photoinduced synthetic procedures were also applied.
For instance, the photochemical cyclization of N-benzylanilines
was used for asymmetrically substituted derivatives at phenan-
thridine side-rings and unsubstituted central ring [24]. The
recently reported photo-conversion of various isocyanide
biphenyls into alkylated phenanthridine derivatives under rather
mild reaction conditions introduced several novelties
(Scheme 8) [25]. The most intriguing is the double role of the
photocatalyst [fac-Ir(ppy)3], consisting of photo-induced gener-
ation of alkyl radical II and oxidation of radical IV to cationic
intermediate V, the latter process also regenerated the catalyst.
Finally, the deprotonation assisted by base resulted in various
6-alkylated phenanthridines in excellent yields (>92%). The
radical inhibitor 2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPO)
was applied to stop the transformation by a single electron
transfer process.
Intriguing combination of irradiation techniques (combined
microwave-assisted and photochemical) offered a new route
toward phenanthridines. Microwave-mediated intramolecular
Diels–Alder cyclization of o-furyl(allylamino)arenes followed
by spontaneous aromatization yielded dihydrophenanthridines,
which upon exposure to UV light (315−400 nm) were oxidized
into (aza)phenanthridines (Scheme 9) [26].
Synthetic pathways based on the transition metal-catalysed
functionalization of carbon–hydrogen (C–H) bonds and forma-
Scheme 8: Easily accessible biphenyl isocyanides reacting under mild
conditions (room temp., visible light irradiation, blue LED light source,
N2, DMF, 10 h) with various common alkyl bromides by application the
two-role catalyst [fac-Ir(ppy)3], gave phenanthridines in good yields
[25].
tions of C–C bonds are often used to access phenanthridines
[27-29]. The most common are high-yield, palladium-based
methodologies under mild conditions, due to their applicability
on a large variety of aryl substituents [16] as well as potential
for stereo and regioselectivity (Scheme 10) [30,31].
Among many examples, very recently a two-step phenanthri-
dine synthesis stands out as a new strategy, characterised by
two roles of the Pd-catalyst in the 1st step, followed by simple
and cost effective oxidation [32] (Scheme 11). This synthesis
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Scheme 9: Microwave irradiation of Diels–Alder adduct followed by UV irradiation of dihydrophenanthridines yielded phenanthridines [26].
Scheme 11: The common Pd-catalyst for the biphenyl conjugation results simultaneously in picolinamide-directed cyclisation; obtained N-picolin-
amide dihydrophenanthridine is easily converted to phenanthridine [32].
Scheme 10: A representative palladium catalytic cycle.
published by Pearson et al. was based on palladium-catalysed
picolinamide-directed sequential C–H functionalization reac-
tions, while readily available benzylamine and aryl iodide were
used as precursors. In the first step the Pd-catalyzed reaction
yielded a biaryl compound. The second step under the catalysis
of Pd(OAc)2 comprised both cyclisation and oxidation in a
single step: a dehydrogenative C–H amination with PhI(OAc)2
as oxidant and removal of the picolinamide group followed by
oxidation with Cu(OAc)2. This strategy afforded phenan-
thridines in moderate to good yields (up to 65% for the second
step).
Bowman et al. reported a palladium-mediated route using
imidoyl-selenides as precursors besides the radical route. Com-
parison of the cyclisation yields for the same set of phenanthri-
dine derivatives revealed an overall better efficiency of the
t-BuO• radical-assisted homolytic aromatic substitution of
diarylimine (Scheme 3) in respect to the Pd(0)-mediated cycli-
sation of imidoyl-selenides (Scheme 12) [16]. Authors proposed
insertion of a Pd(0) species into the carbon–selenium bond, fol-
lowed by carbo-palladation onto the phenyl ring. This inter-
mediate then undergoes rapid rearomatization with the loss of
HPdSePh to give the phenanthridine.
Candito et al. reported a new and highly efficient method for the
synthesis of variously substituted phenanthridine derivatives
employing N-unsubstituted imines or N-silylimines [33]. The
method is limited to ortho-substituted aryl iodides as starting
material and also requires a convenient imine derivative
allowing the cleavage of the nitrogen-attached group (R5) at
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Scheme 13: Palladium-catalysed phenanthridine synthesis.
Scheme 14: Aerobic domino Suzuki coupling combined with Michael addition reaction in the presence of a Pd(OAc)2/K3PO4 catalytic system in water
[34,35].
Scheme 15: Rhodium-catalysed alkyne [2 + 2 + 2] cycloaddition reactions [36].
Scheme 12: Pd(0)-mediated cyclisation of imidoyl-selenides forming
6-arylphenanthridine derivatives [16]. The insertion of the Pd(0)
species into the carbon selenium bond followed by fast rearomatisa-
tion to phenanthridine is involved with the loss of HPdSePh.
some point in the catalytic cycle (Scheme 13). It is noteworthy
that polar solvents (DMF, N-methylpyrrolidone, and acetoni-
trile) had favourable impact on the reaction.
Ghosh, Dhara et al. also reported a synthesis of substituted
phenanthridines based on palladium-mediated Suzuki coupling
(Scheme 14) [34,35]. Aerobic ligand-free domino Suzuki
coupling–Michael addition reaction in the presence of
Pd(OAc)2 and K3PO4 as a catalytic system in H2O was catal-
ysed by palladium nanoparticles, that were generated in situ in
water with the elimination of acetone.
One of the major issues is the preparation of polysubstituted
phenanthridines, in particular asymmetrically positioned on one
of phenyl side-rings. An intriguing approach over rhodium-
catalysed alkyne [2 + 2 + 2] cycloaddition reaction [36]
(Scheme 15) offered a highly efficient method with excellent
regioselectivity (in case of bulky groups), with additional
advantage of the C-6 fluorinated methyl substituent – promising
for PET probe development.
Most of the metal catalysts employed for phenanthridine syn-
thesis are rather expensive; therefore efforts were made to
replace them with cheaper analogues. One successful approach
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Scheme 16: The O-acetyloximes derived from 2′-arylacetophenones underwent N–O bond cleavage and intramolecular N-arylation, followed by
cross-coupling or directed C–H arylation [37].
Scheme 17: C–H arylation with aryl chloride in the presence of a simple diol complex with KOt-Bu (top) [39]; for some cases it worked also in the
absence of diol (bottom) [40].
included iron(III) acetylacetonate in acetic acid as catalytic
agent (Scheme 16) [37], whereby O-acetyl oximes obtained
from 2′-arylacetophenones underwent N–O bond cleavage and
intramolecular N-arylation. The following conventional cross-
coupling or directed C–H arylation resulted in substituted
phenanthridines.
Homolytic aromatic substitution (HAS) by an aryl radical was
used for the construction of biaryl motifs as alternative to tran-
sition metal-catalysed C–H bond arylation. That approach was
also implemented in the two-component cyclization in the
synthesis of phenanthridine derivatives [38]. The starting
isocyanide biphenyl (similar to Scheme 8) reacts with the
phenyl radical generated from phenylboronic acid and a
manganese salt followed by spontaneous cyclisation and aroma-
tisation.
Trying to omit the expensive metal catalysts, several successful
attempts of a transition metal-free approach for phenanthridine
synthesis were reported. For instance application of a simple
diol combined with KOt-Bu resulted in intramolecular C–H
arylation to give the respective phenanthridine derivatives
(Scheme 17 top) [39]. More recently, a similar procedure
worked just in the presence of KOt-Bu by intramolecular
homolytic aromatic substitution (HAS), without the use of an
organic molecule as ligand to give benzo[c]phenanthridine
derivatives (Scheme 17 bottom) [40].
An unique approach to the phenanthridine core starting from a
simple disubstituted aniline relied on the aza-Claisen rearrange-
ment, ring-closing enyne metathesis and Diels–Alder reaction
[41] (Scheme 18). The obtained phenanthridine derivatives
were polysubstituted at the phenyl side-rings, while retaining
the unsubstituted central heterocyclic double bond. The diver-
sity of the aza-Claisen rearrangement allows the application of
this approach to other related heterocyclic systems.
The preparation of a new variety of analogues, namely 6-phos-
phorylated phenanthridines was very recently reported, whereby
central-ring cyclisation was accompanied with simultaneous
phosphorylation [42] (Scheme 19). The particular importance of
this economic and highly efficient synthetic method is the
complementarity of the starting material, the easy availability of
2-isocyanobiphenyls, which could be converted to variously
substituted phenanthridines in several ways (Scheme 7 and
Scheme 8).
Because of the recent strong focus on benzophenanthridines due
to their potent antitumor and antiinfectious activities [43], we
have chosen one recent synthetic approach (differing from afore
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Scheme 18: The subsequent aza-Claisen rearrangement, ring-closing enyne metathesis and Diels–Alder reaction – a new “three-atom economic
process” of phenanthridine synthesis [41].
Scheme 19: Phenanthridine central-ring cyclisation with simultaneous radical-driven phosphorylation [42].
Scheme 20: Three component reaction yielding the benzo[a]phenanthridine core in excellent yields [44].
listed examples) to benzo[a]phenanthridines as close analogues
of phenanthridine (Scheme 20) [44]. The synthesis by multi-
component tandem reaction/carbocyclization starts with the for-
mation of a 4-aryl-3-arylethynylisoquinoline from 2-bromo-
benzaldehyde/tert-butylamine/1,3-diyne. The second (in situ)
step is based on the ring closure, either via gold/silver-catal-
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Scheme 21: a) Reaction of malononitrile and 1,3-indandione with BEP to form the cyclised DPP products; b) pH controlled reversible cyclisation
process of DPP compounds [45].
ysed intramolecular hydroarylation or via iodo-catalysed regios-
elective 6-endo-dig electrophilic cyclization.
Kitson et al. synthesized a class of 2,3-dihydro-12H-
pyrrolo[1,2-f]phenanthridine (DPP) derivatives starting from
malononitrile and 1,3-indandione as the initial nucleophiles,
which reacted with N-bromoethylphenanthridinium bromide to
give DPP-dicarbonitrile and DPP-indandione, respectively.
Particularly an interesting property of these DPP products is the
reversible, pH controlled ring-opening-cyclisation process,
whereby at acidic conditions DPP undergoes rearomatisation of
the phenanthridinium ring system (Scheme 21a), which at basic
conditions (TEA) switches back to the initial DPP structure
(Scheme 21b) [45].
Summary of synthetic advances
Among many given examples of the phenanthridine synthesis,
currently two most common routes are the synthesis under
radical conditions [12-24] and the synthesis based on transition
metal-catalysis [15,27-37].
The main advantage of the radical-based phenanthridine syn-
thesis is easy available and generally cheap starting material
(benzotriazole, aminobiphenyl, arylaldehyde, N-(ortho-
halobenzyl)arylamines, oxime carbonates, isocyanobiphenyls,
etc.). Phenanthridines are usually obtained within 2–3 reaction
steps, by application of different radical initiators. An intriguing
alternative is the radical generation by UV irradiation with or
even without a photocatalyst. The major advantage of radical-
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Figure 1: Schematic presentation of the intercalative binding mode by the neighbour exclusion principle and important structural features of ethidium
bromide: A) amino substituents responsible for fluorescence increase upon DNA intercalation; B) phenyl substituent for steric control and also impact
on fluorimetric properties; C) permanent positive charge for aqueous solubility and electrostatic attraction to the DNA or RNA phosphate backbone.
based routes are usually mild reaction conditions, while reac-
tion yields, after optimization of the synthesis parameters, span
from 50–90%, mostly depending on the substituents attached to
the starting material. The radical-based synthesis is typically
used for the preparation 6-aryl or 6-alkylphenanthridine deriva-
tives and 6-phosphorylated analogues, equipped with one or
two additional substituents, usually positioned on the phenan-
thridine positions C1–4 or position C8.
Similarly to the radical-based synthesis, a synthetic approach
based on transition metal-catalysis also allows the phenanthri-
dine preparation from easily available starting material (benzyl-
amine, aryl iodide, imines, etc.) in few reaction steps, under
mild reaction conditions and with yields within the 50–90%
range. The great advantage of this approach is the very broad
versatility in preparation of phenanthridine derivatives, poly-
substituted on the phenyl side-rings by a large variety of
substituents, as well as stereo- and regioselectivity (particularly
for the bulky groups). Nevertheless, due to the most common
metal catalyst (palladium) this method is significantly more
expensive and less environmentally friendly than radical-based
methods. To address these disadvantages, in the last decade par-
ticular attention was given to the replacement of the expensive
palladium catalyst, for instance by iron [37]. However, major
impact was made by introduction of the cheap and environmen-
tally friendly intramolecular homolytic aromatic substitution
(HAS) reaction with the aid of the organo-catalysis; although it
is currently applicable for the preparation of only a limited
variety of phenanthridine derivatives and benzophenanthridines
but future prospects are very promising.
Aside two most common ways to prepare the phenanthridine
moiety, here are described several innovative approaches, with
potential to be developed for a large versatility of phenanthri-
dine derivatives or application of previously not used starting
materials (for instance microwave-mediated intramolecular
Diels−Alder cyclization of o-furyl(allylamino)arenes).
For the most of DNA or RNA targeted applications the phenan-
thridine is converted to the positively charged phenanthri-
dinium cation by simple alkylation of the phenanthridine hete-
rocyclic N5 nitrogen (thus giving permanent positive charge) or
by the N5 nitrogen protonation at weakly acidic conditions
(pK(N5) ca. 5.5–6) yielding reversible positive charge. Here are
also described novel approaches to reversible positively charged
(DPP and DIP derivatives [45]), which are related to remark-
able structural features of the naturally occurring benzophenan-
thridine alkaloids – pH-dependent structural transition between
the iminium (positively charged) and alkanolamine (neutral)
form [46].
Structural features of phenanthridines and
phenanthridinium cations related to DNA and
RNA binding
Structural studies on the phenanthridine system were mostly
driven by its most widespread use as DNA and RNA interca-
lator (Figure 1) and/or fluorescent marker (ethidium bromide/
propidium iodide) for ds-DNA and ds-RNA [47]. The phenan-
thridine structural features incorporate a unique set of prop-
erties related to the interaction with DNA and RNA (Figure 1):
size and curvature of the aromatic surface corresponds to the
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
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Figure 2: Urea and guanidine derivatives of EB with modified DNA interactions [57].
basepair shape, whereas the high polarizability (and permanent
positive charge of N-5 alkylated derivatives) also plays an
important role in aromatic and electrostatic interactions with
polynucleotides. Moreover, non-covalent interactions with
DNA and RNA can be reversibly controlled by a pH-induced
positive charge at the heterocyclic nitrogen N-5, and strong
electron affinity and polar groups at the 3 and/or 8 position of
the phenanthridine can efficiently and predictably regulate the
spectroscopic response (UV–vis and fluorescence) of the chro-
mophore [48].
The understanding of the intercalation process requires a
detailed knowledge of the energetics, thermodynamics and
structural equilibrium – surprisingly few studies endeavoured to
determine important parameters for such classical intercalator as
ethidium bromide [49]. The most recent and very extensive
theoretical study compared positively charged ethidium bro-
mide and its neutral analogue, revealing detailed description of
the forces included in the intercalation process, stressing the
dispersion energy as a control factor [50]. Moreover, a number
of kinetic measurements provided for the binding of ligands to
DNA additionally clarify mechanistic details that are not
apparent from equilibrium measurements [51].
Another, very comprehensive approach, relying mostly on the
experimental data of X-ray crystallography, UV–vis, fluores-
cence and NMR spectroscopy, determined that the fine inter-
play between electron donating and electron withdrawing
effects mediated by its nitrogen atoms defines the spectros-
copic properties of ethidium bromide (EB) and its derivatives
[48]. It turned out that, despite the positive charge of ethidium
bromide, most of ethidium's aromatic carbon and hydrogen
atoms have high electron densities compared to the
6-phenylphenanthridines. Thus, the electron-donor properties of
the exocyclic amines, especially at 8-position have a stronger
influence on the electron density of aromatic atoms than the
electron withdrawing effects of endocyclic iminium. Fine
tuning of electron properties of EB can be easily achieved via
chemical modulation of its amino groups at 3 and 8 positions of
the phenanthridine ring [52,53]. Systematic changing of the
ethidium bromide exocyclic amines into guanidine, pyrrole,
urea, and various substituted ureas revealed importance of elec-
tron-donor properties of substituents at the 3- and 8-position of
the phenanthridinium relative to the unmodified primary amino
groups. Namely, derivatives of EB having substituents with
weaker electron-donor properties exhibited a stronger fluores-
cence emission than EB, while a stronger electron-donating
substituent exhibited a much lower fluorescence emission. Such
behaviour could be attributed to the ethidium exocyclic amines
enabling by electron donation a non-radiative decay of phenan-
thridinium excited state, rather more likely than the previously
proposed mechanism of water-induced deprotonation of
phenanthridinium exocyclic amines, causing excited chro-
mophore fluorescence quenching [54,55].
Taking into account the research results of several other groups,
a general rule could be drawn that phenanthridines with no
amino groups yield strong fluorescence in water but emission is
totally quenched by DNA binding; one amino group at (usually)
position 8 results in only a small fluorescence change in the
complex with DNA, while two amino groups in 3,8-position
result in a weak fluorescence with strong emission increase
upon DNA binding [52,53,56].
A pronounced influence of the substituent at phenanthridine
position 6 on the optical properties of the chromophore also had
significant impact on the binding affinity toward ds-DNA. The
comparison of three substituents in 6-position, 4-N,N-diethyl-
aminophenyl, phenyl (EB) and methyl, revealed that the first
one exhibits the strongest DNA binding affinity and the
strongest fluorescence enhancement. That was related to the
twist angle in the excited state between the 6-phenyl ring and
the phenanthridinium chromophore, which controls the non-
radiative relaxation [56].
Substituted phenanthridine derivatives
In particular guanidine- and urea-substituted derivatives
attracted a lot of attention due to the different interactions with
various DNA and RNA. The ability of ethidium bromide
analogues to inhibit the HIV-1 Rev–Rev Response Element
(RRE) interaction, as well as their affinity to calf thymus
(ct)DNA was analysed. One derivative (Figure 2, 1) displayed
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
2941
Figure 3: Structure of mono- (3) and bis-biguanide (4) derivative. Fluorescence (y-axis normalised to starting fluorescence of free 4,
c = 1.0 × 10−6 mol dm−3) was quenched by GC-DNA and increased for AT-DNA. Inset: induced (I)CD spectra λ > 280 nm of 4 (r(4)/DNA = 0.3;
c(DNA) = 2 × 10−5 mol dm−3) – strong positive ICD band for AT-DNA and negative ICD band for GC-DNA. Adapted with permission from [58]. Copy-
right 2011 The Royal Society of Chemistry.
an enhanced affinity for HIV-1 RRE and a lower DNA affinity
(i.e., lower mutagenic activities) compared with ethidium bro-
mide. A recent study showed that substitution of both ethidium
bromide (EB) and exocyclic amines by guanidines converted
the classical intercalator (EB) into a DNA minor groove binder
[57]. The most intriguingly, binding mode change did not
weaken the DNA affinity, thus the affinity of guanidine deriva-
tive 2 (Figure 2) towards AT-rich DNA sequences was signifi-
cantly stronger compared to ethidium and comparable to that of
the known DNA minor groove binder furamidine.
The above mentioned guanidine-induced switch of the DNA-
and RNA-binding mode [57] inspired a design of derivatives
equipped with biguanide groups at 3 and/or 8 positions [58]
(Figure 3), under the presumption that the extended H-bond-
rich system should increase the ability of the chromophore to
differ among various shapes of ds-DNA- and ds-RNA-grooves.
Both, mono- (3) and bis-biguanide (4), efficiently discriminate
between dAdT and dGdC polynucleotides by opposite changes
of compound fluorescence, as well as opposite induced (I)CD
bands (Figure 3). Moreover, both, 3 and 4, show the binding to
AU-RNA by a different fluorimetric and CD response in respect
to DNA-binding. Observed recognition between various DNA
and RNA polynucleotides was attributed to the switch of the
binding mode (intercalation into dGdC-DNA and AU-RNA and
minor groove binding into dAdT-DNA).
A common strategy for the modification of DNA- and RNA-
targeting molecules by preparation of homo-dimers was also
implemented on the phenanthridine moiety – many ethidium
bromide-based dimers were prepared and reviewed in the last
two decades of the 20th century, thus here will be presented
results from 2000 on.
Systematic variation of steric and/or electrostatic effects by
means of type, number, length and flexibility of linkers
connecting two phenanthridine units is presented in Scheme 22.
The ability of switching on/off the charge of phenanthridine
heterocyclic N5 via its protonation at weakly acidic pH (pK
5–6) was utilized in a design of phenanthridine derivatives to
alter significantly their binding preferences toward polynu-
cleotides. Among several examples, the most intriguing pH
controlled binding of nucleotides and nucleic acids showed bis-
phenanthridine triamine [59] (8, Scheme 22). Compound 8
intercalated with only one phenanthridinium subunit into all
ds-DNA and ds-RNA, while additional interactions of the other
subunit within the grooves finely tuned the recognition between
various ds-polynucleotides. The sensitivity of spectroscopic
response was particularly pronounced for ss-RNA, whereby at
weakly acidic pH compound 8 exhibited specific fluorimetric
sensing of poly(G) among other studied ss-polynucleotides.
Cyclic cage-like bis-phenanthridinium derivatives (Scheme 16;
general structure 7), with a rigid structure allowing accommo-
dation of only one nucleobase, showed pronounced ss-RNA
over ds-RNA/DNA selectivity [60], whereas more flexible
cyclic (6) and acyclic analogues (5) [61] revealed opposite pref-
erence, stressing the importance of steric control over selec-
tivity (Scheme 16). The selectivity of 7 was based on the switch
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Scheme 22: Bis-phenanthridinium derivatives (5–7; inert aliphatic linkers, R = –(CH2)4– or –(CH2)6–): rigidity of a “cage” – steric control of binding
site. Triamine-linked bis-phenanthridine 8, note reversible doubling of positive charges at pH 5 in respect to neutral conditions (pH 7). Bis-urea
phenanthridines (general structure 9): different from amino analogues (5) by fluorimetric response and DNA- and RNA-binding modes.
of binding mode; the very rigid pocket between two phenanthri-
dinium moieties allows only bis-intercalation into single-
stranded polynucleotides and only binding with double-stranded
polynucleotides in non-intercalative mode (most likely within
the DNA and RNA grooves). Moreover, the cage-like binding
pocket of bisphenanthridiniums 7 showed to be sensitive to the
minor structural differences between mononucleotides, yielding
a very selective fluorimetric response upon binding of AMP in
respect to other nucleotides. In addition, the observed selec-
tivity towards poly(G) and poly(A) can be beneficial in bio-
logical applications for instance to influence the mRNA-func-
tion via binding to the poly(A) tail [62-64] and inhibition of the
HIV-1 replication by targeting recognition of the polypurine
tract by reverse transcriptase [65].
In a series of N5-protonated urea-substituted bis-phenanthri-
dinium derivatives (Scheme 22, general structure 9), the varia-
tion of the linker length connecting two urea-phenanthridinium
conjugates significantly influenced the efficiency of intramolec-
ular interactions between two phenanthridinium subunits and
consequently their DNA- and RNA-binding mode (shorter
linker–minor groove binding, the longest linker–intercalation)
[66,67]. In addition, the derivative with the longest linker was,
to the best of our knowledge, the first bis-phenanthridine-based
intercalator able to differentiate between A–U(T) and G–C base
pairs by sign of opposite fluorimetric response. An introduction
of the permanent positive charge by methylation of the hetero-
cyclic nitrogen changed the binding mode of the conjugates
with shorter linkers from minor groove binding to intercalation
and also resulted in significantly higher biological potency in
respect to non-methylated analogues [67]. Moreover, the
observed DNA and RNA interactions were also distinctively
different from previously studied aliphatic-linker analogues (5),
pointing out the decisive role of urea-linker interactions.
The common approach to complex small molecules targeting
DNA and RNA usually required a number of consecutive syn-
thetic steps, which made modification of the interesting struc-
tures a laborious and time-consuming task, quite often being the
bottle-neck in the structure–activity relation research. With aim
to facilitate structural modifications in DNA and RNA targeting
by oligo-aryl derivatives, new amino acids with phenanthridine
attached to the side chain were prepared and the solid phase
synthesis of novel peptide-bridged bis-phenanthridine deriva-
tives was developed (Figure 4) [68], whereby the position of the
DNA-active chromophore in the peptide backbone as well as
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Figure 5: General structure of 45 bis-ethidium bromide analogues. Reproduced with permission from [69]. Copyright 2012 Elsevier Ltd.
the structural characteristics of the linker between them can
easily be modified. In the first series of peptide-bridged bis-
phenanthridine derivatives, derivative 11 with the shortest
linker formed an intramolecular excimer, characterised by the
specific fluorescence band sensitive to the pH as well as on the
interactions with ds-DNA. Interestingly, all peptide-based
phenanthridines revealed excellent water solubility combined
with low in vitro toxicity, thus being good candidates for devel-
opment of new safe fluorimetric DNA and RNA dyes.
Figure 4: Series of amino acid–phenanthridine building blocks
(general structure 10; R = H; Gly) and peptide-bridged bis-phenanthri-
dine derivatives (general structure 11; R = X; Gly; Gly–Gly) [68].
Another large series of phenanthridinium-homodimers was
constructed by linking two ethidium bromide subunits by
peptide-like linkers of variable flexibility and rich in hydrogen-
bonding possibilities within the DNA grooves (Figure 5). The
resulting bis-intercalators (in comparison to the monomeric
analogues) revealed significantly increased DNA-binding
affinity and consequently enhanced telomerase and reverse tran-
scriptase inhibition [69].
Conjugates of phenanthridine with other DNA
and RNA active moieties
Another common approach to increased selectivity of DNA-
and RNA-targeting small molecules is the design of complex
conjugates consisting of several DNA- and RNA-active parts
(e.g., intercalator, groove binder, electrostatically binding
component, various sterically directing parameters). The
phenanthridine moiety was quite often used as presumably
intercalating unit, although in some cases a switch of the
binding site to the minor groove was reported.
In an effort to influence DNA sequence-selective recognition by
small molecules (MW <1000), our group prepared a series of
phenanthridine derivatives with one or two nucleobases cova-
lently attached at the 3 and/or 8 positions of the phenanthridine
ring (Scheme 23). The phenanthridinium–nucleobase conju-
gates did not show targeted selectivity toward complementary
nucleotides in aqueous medium due to the strong competition of
bulk water with the expected hydrogen bonds [70,71]. Fortu-
itously, the hydrophobic environment within the common DNA/
RNA binding sites allowed H-bonding-based recognition of
some complementary polynucleotide sequences. However, the
recognition pattern was not straight-forward; for instance
N5-protonated phenanthri-dinium–adenine derivative 12
successfully recognized a complementary poly(U) sequence
[72] (Scheme 23), but this recognition was completely lost upon
introduction of a permanent positive charge by methylation of
phenanthridine-N5 13 [71]. Intriguingly, N5-methylated
phenanthridine–adenine conjugate 13 exhibited preferred
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Scheme 23: Top: Recognition of poly(U) by 12 and ds-polyAH+ by 13; bottom: Recognition of poly(dA)–poly(dT) by 14, intramolecular H-bonds
marked by circles. Reproduced with permission from [72,73], copyright 2002, 2005 The Royal Society of Chemistry and with permission from [71],
copyright 2003 John Wiley & Sons, Inc.
binding to peculiar protonated poly AH+ double stranded helix
(Scheme 23) [71]. Attachment of two adenines to N5-proto-
nated phenanthridinium completely abolished interactions with
DNA and RNA due an extensively self-stacked structure but the
bisuracil–phenanthridinium conjugate 14 was able to distin-
guish between alternating and consecutive AT sequences by
peculiar combination of aromatic stacking and hydrogen-
bonding interactions [73,74].
At variance to phenanthridinium–nucleobase conjugates
(Scheme 23), which were not able to differentiate among
mononucleotides, some bis-phenanthridinium–nucleobase
conjugates provided a more convenient binding site for the
nucleobase. For instance, adenine derivative 15 (Figure 6)
selectively recognized the complementary nucleotide (UMP) by
specific change in the UV–vis spectrum of phenanthridine
subunits and high affinity [75]. Molecular modelling studies
proposed a structure of the 15–UMP complex stabilized by a set
of intra- and intermolecular stacking interactions and intermole-
cular hydrogen bonds unique for derivative 15 interaction with
UMP but not possible with other nucleotides. Moreover,
mentioned bis-phenanthridinium–nucleobase conjugates also
exhibited complex interactions with various ds- and ss-DNA
and ds- and ss-RNA, whereby the thermal denaturation and ICD
signal-based sensing was highly sensitive to the polynucleotide
basepair composition and secondary structure [76]. However,
the low solubility of the studied systems hampered NMR
studies and the very complex set of possible interactions did not
allow accurate structural explanation of observed ICD recogni-
tion.
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Figure 6: The bis-phenanthridinium–adenine derivative 15 (LEFT) showed selectivity towards complementary UMP; structure of the 15–UMP com-
plex (RIGHT) obtained by molecular modelling. Reproduced with permission from [75]. Copyright 2010 Elsevier Ltd.
Laborious synthetic procedures for the preparation of bis-
phenanthridine–nucleobase conjugates initiated a novel, conver-
gent and much more flexible approach relying on solid phase
peptide synthesis described earlier (Figure 4). In such a manner
prepared phenanthridine–thymine conjugates [77], intercalated
into ds-DNA whereby binding was marginally influenced by at-
tached thymine and the peptide backbone. More intriguing was
the observed excimer fluorescence emission and the very
specific CD spectrum of pentapeptide confirming the very effi-
cient phenanthridine–thymine–phenanthridine stacking. The
obtained results support efficient and predictable self-organisa-
tion of sterically crowded oligo-phenanthridine peptides
(Figure 4, [68]) as well as analogues containing other (DNA
and RNA binding) aromatic moieties [77], which as a proof of
principle support future design of analogous peptide libraries
for combinatorial approach to recognition of various DNA and
RNA targets.
A structure–activity search revealed several phenanthridinium
derivatives as promising binders to DNA:RNA hybrid struc-
tures [78]. Based on their previous work [79], Arya and
coworkers designed neomycin–methidium conjugate 16
(Figure 7) [80], which selectively recognized the DNA:RNA
hybrid duplex (poly(dA):poly(rU)) with sub-nanomolar affinity,
much higher than the affinities shown for traditional aminogly-
coside–nucleic acid targets. This joins the mentioned EB
analogue to a small number of ligands that bind DNA:RNA
hybrid structures. Latter play crucial roles in a number of bio-
logical processes (transcription, reverse transcription [79], the
priming of DNA prior to replication [81], participating in
different types of enzymatic activity, notably telomerases [82]
and HIV RNase).
Ethidium bromide was introduced as a part of a heterogenic
two-chromophore system, to take advantage of very efficient
FRET energy transfer process (77%) from fluorescein to the
Figure 7: The neomycin–methidium conjugate targeting DNA:RNA
hybrid structures [80].
RNA-intercalated phenanthridinium fluorophore (Figure 8, left)
[83]. The resulting fluorescent dye exhibited improved
ds-RNA-marker properties in comparison to other phenanthri-
dinium analogues by means of signal brightness, signal-to-back-
ground noise and increased fluorescence half-lifetime. The
same dye was also applied as convenient reporter for si-RNA
(Figure 8, right) [84]. In parallel the designed and tested cova-
lently linked ethidium bromide–ruthenium(II) complex also
proved to be an imaging probe whose fluorescence intensity and
lifetime changes substantially in the presence of RNA [85], thus
supporting a strategy of phenanthridinium incorporation into the
heterogenic two-chromophore system.
Phenanthridines are rarely combined with moieties covalently
interacting with DNA and RNA. One of the most promising
examples reported recently revealed that in a series of mono
functional, cationic platinum(II) compounds, phenanthriplatin
displayed a greater cytotoxic activity than either cisplatin or
oxaliplatin despite a fact that binding to DNA induces a little
distortion in the double helix (covalent adducts with DNA) [86].
The increased activity was attributed to improved cellular
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Figure 8: Two-colour RNA intercalating probe for cell imaging applications: Left: Chemical structure of EB-fluorescein conjugate (FLEth) and cartoon
depicting the energy transfer process from fluorescein to the intercalated phenanthridine fluorophore. Reproduced with permission from [83]. Copy-
right 2008 American Chemical Society.; Right: Convenient Reporter for Small Interfering RNAs fluorophore. Reproduced with permission from [84].
Copyright 2009 American Chemical Society.
Figure 9: The ethidium bromide nucleosides 17 (top) and 18 (bottom). DNA duplex set 1 and 2 (E = phenanthridinium intercalation site). Reproduced
with permission from [87]. Copyright 2004 American Chemical Society.
uptake and consequent inhibition of the cellular life cycle,
whereby inhibition was additionally correlated to more expe-
dient binding to nucleobases (5'-dGMP) in respect to less effi-
cient binding of sulfur-containing nucleophiles present in resis-
tance processes within the cell.
Phenanthridine covalently bound to DNA and
RNA
The phenanthridine aromatic moiety curvature nicely fits the
shape of an average DNA and RNA basepair, while the length
allows the incorporation of considerably long substituents at
3,8- positions available for attachment to DNA and RNA and/or
various additional non-covalent interactions with the polynuc-
leotide backbone.
The ethidium bromide incorporated as an artificial DNA base
(18, Figure 9) at specific sites in duplex DNA was used to study
photoinducible charge transfer processes [87]. Upon attach-
ment to the DNA chain the phenanthridinium base (E, Figure 9)
was efficiently intercalated into the DNA oligonucleotide, not
disturbing the position of adjacent basepairs nor the comple-
mentary oligonucleotide strand (abasic site X). Though,
ethidium 2’-deoxyribofuranoside (17) [88] revealed chemical
instability and was therefore replaced with an acyclic linker
system [87]. However, in a later work the acyclic linker was
again modified to correspond by length to the deoxyribofura-
noside, whereby it was proven that structural changes do not
influence significantly the EB insertion into the double helix,
nor EB spectroscopic properties [87,89].
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Figure 10: Left: various DNA duplexes; DNA1 and DNA2 used to study the impact on the adjacent basepair type on the EB fluorescence (repro-
duced with permission from [90], copyright 2004 John Wiley & Sons, Inc.) and DNA1,2,3,4-XY studying the EB fluorescence quenching by 7-deaza-
guanine (B) as a function of different position of abasic site (S). Reproduced with permission from [91] Copyright2005 Royal Society of Chemistry.
Right: structure of incorporated EB (18) and of the abasic site (S).
Further studies revealed that various adjacent base pairs
(Figure 10, A–T in DNA1, G–C in DNA2) did not significantly
influence the spectroscopic properties of the ethidium bromide
[90], while usage of noncovalently bound electron-acceptor
showed applicability of the phenanthridinium–DNA system for
studies of electron transfer in DNA [90]. Thus the EB-nucleo-
base fluorescence was not sensitive to the type of naturally-
occurring adjacent basepairs [90] but showed to be sensitive to
major erroneous ds-DNA sites (e.g., abasic sites) [91]. Namely,
by using the well-known system of EB-fluorescence quenching
by 7-deazaguanine incorporated within modified oligonucleo-
tides, it showed that the abasic site (S) either one base pair away
(DNA1-XY and DNA2-XY) or two base pairs away (DNA3-
XY and DNA4-XY) from the EB chromophore showed an
enhanced fluorescence quenching compared to the matched
duplexes [91].
Among many studies of charge transfer in DNA, several
applying ethidium bromide, revealed an unexpected complexity
of the process, pointing out the importance of the DNA/EB
complex flexibility on the efficiency of the transfer. A study of
comparatively flexible DNA/EB complex, EB covalently at-
tached to the 5’-end of oligonucleotides, in detail described the
rate and distance dependencies of charge transfer through DNA
[92,93]. A more rigid type of EB-binding, whereby the
EB-nucleobase was incorporated close to the centre of the DNA
oligomer in combination with two different charge acceptors
(7-deazaguanine as an electron hole acceptor and a 5-nitroin-
dole as a suitable electron acceptor) [94], showed similar rates
and distance dependencies for both, electron and hole transfer.
The obtained results [92-94] stress the importance of DNA-
basepair dynamics for the electronic transfer processes in DNA-
stacks. The efficiency of transfer is rather more controlled by
motions of chromophores involved in aromatic stacking of
DNA-reporter complex than with rigid aryl-stacking, thus
suggesting the presence of a base gating mechanism (for the
here presented EB/DNA systems on the 10–100 ps scale).
Phenanthridine analogues
One of the main incentives that increased interest in phenan-
thridines was the large family of naturally occurring close
analogues, mostly of extended aromatic moieties (e.g., benzo-
phenanthridines). Their distinctive biomedical properties
resulted in a considerable amount of research and large number
of publications, hampering their detailed description in this
review. Nevertheless, several chosen examples of phenanthri-
dine analogues will be presented.
The phenanthridine analogues, 4,9-diazapyrenium cations (very
scarcely studied) [95], revealed a number of very intriguing
properties upon binding to DNA and RNA. For instance, the
closest analogue to ethidium bromide 19 (Figure 11) showed
opposite fluorescence response upon binding to double-stranded
GC-DNA and GC-RNA (quenching of emission) and AU(T)
(emission increase) [96]. The only plausible structure of interca-
lated 19 requires parallel positioning of 19 and adjacent base
pairs’ long axes, consequently positioning the bulky phenyl
substituents of 19 in opposite DNA grooves – thus 19 exhibits
rare threading intercalation binding into double-stranded
polynucleotides. Furthermore, derivative 19 formed two types
of complexes with ss-RNA, a more stable one with a well
organised, possibly helical structure (ICD evidence) close to
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Figure 11: Structure of 4,9-DAP derivative 19; Rright: MIAPaCa-2 cells stained with 10 μM 19 after 60 and 120 min incubation, respectively. Magnifi-
cation 630×. Reproduced with permission from [95]. Copyright 2000 Royal Society of Chemistry.
saturation of poly(U) (r ≈ 1) and less stable complexes with the
other ss-RNA, characterised by decreased CD bands of polynu-
cleotides. At variance to other 4,9-diazapyrenium compounds
that lack the amino groups in positions 2 and 7, derivative 19
exhibited higher affinities and larger stabilisations of ds-DNA
and ds-RNA probably due to additive interactions of its amino
substituents within the polynucleotide binding site. All 4,9-DAP
derivatives also showed considerable antiproliferative activity,
interestingly only 19 having strong, micromolar activity in vitro
but negligible in vivo toxic effects in mice [97]. Strong fluores-
cence of 19 allowed monitoring of the very efficient cellular
uptake (Figure 11), upon which red colour of 19 accumulated in
cell nuclei – intriguingly after only 2 hours fluorescence colour
changed to yellow (Figure 11, right) and the dye distributed
over the cytoplasm pointing out to the metabolic modification
of the compound.
The new, easily accessible analogue, dihydroimidazophenan-
thridinium cation characterised by cyclic structure connecting
positions 5 and 6, showed promising antiproliferative activity
[3,98,99]. Molecular modelling results and some preliminary
experiments suggest intercalative binding mode, however up till
now interactions with various DNA and RNA were not studied
in detail.
One of several reasons for the increased research on phenan-
thridines is the discovery of naturally occurring analogues, e.g.,
some protoberberine alkaloids (Figure 12, sanguinarine and
chelerythrine), widely distributed in several botanical families
exhibiting many therapeutic applications. Very extensive results
would require a focused review, thus some examples are listed
below as outline of the importance.
Most of the sanguinarine (20) and chelerythrine (21) deriva-
tives were typical DNA and RNA intercalators [100], some of
them showing also intriguing interactions with ss-RNA, poly(A)
[46]. However, either intercalative binding mode or structural
similarity to EB did not hamper their biomedical applications.
For instance, in a series of 5-methylbenzo[c]phenanthridinium
derivatives, based on combination of sanguinarine (20)/chelery-
thrine (21) structures [101], the presence of a 1-phenyl or
12-phenyl  subs t i tuen t  on  2 ,3 ,8 ,9- te t ramethoxy-5-
ethylbenzo[c]phenanthridinium chloride [102] significantly
enhances the antibacterial (Staphylococcus aureus and Entero-
coccus faecalis) activity relative to sanguinarine. Another
example, using the strategy of bioactivity-guided fractionation,
the bioactive compound chelerythrine (21, a quaternary
benzo[c]phenanthridine alkaloid) was isolated from Chelido-
nium majus L. [103]. In addition to strong antihelmintic activity
(against D. intermedius), chelerythrine also showed antimicro-
bial, antifungal and anti-inflammatory activity [104].
Figure 12: Examples of naturally occurring phenanthridine analogues.
Discussion of the presented results and
perspectives
The data presented in this review endeavoured to stress the
outstanding properties of the rather simple and, due to the
substantial advance in synthetic approaches, now readily avail-
able moiety (phenanthridine). Within the last 15 years signifi-
cant research efforts invested in the phenanthridine and phenan-
thridinium structure–DNA and RNA-binding relations resulted
in a significantly advanced understanding of the chromophore
system in the free form and even more important in complex
with ds-DNA and ds-RNA.
Beilstein J. Org. Chem. 2014, 10, 2930–2954.
2949
Table 1: Binding affinities (log Ks); thermal denaturation effects and proposed binding modes of chosen phenanthridine and phenanthridinium deriva-
tives with natural and synthetic polynucleotides: ds-DNA and ds-RNA.
Ligand pH log Ksa(∆Tmb) / Binding modec
ctDNA dA–dT dAdT–dAdT rA–rU dG–dC rG–rC
1 7.5 5.6d ,(–) / IC – – – –
4
5 –, (20.6) / MG 7.4, (29.5) / MG –, (25.0) / MG 7.4, (35.4
e/–1.8)
/ IC 6.6, (–) / IC –
7 –, (5.6) / MG 6.5, (9.8) / MG –, (10.3) / MG 5.7, (5.0) / NSA 5.8, (–) / IC
5
R = (CH2)4
6.2 – 5.2, (–
f/45.3) / IC +
ESI –
5.7, (–f/21.5) / IC
+ ESI –
6.5,(–) / IC
+ ESI
5
R = (CH2)6
6.2 – 5.7, (–
f/42.5) / IC,
NSA –
8.0, (–f/20.7) /
IC, NSA –
6.3,(–) / IC,
NSA
6
R = (CH2)6
6.2 – –g, (25.6) / GB – 5.3, (3.9) / GB – 6.5,(–) /GB
7 6.2 – 6.0, (–) / GB, ESI – –g ,(–) / GB, ESI – 5.7,(–) /GB, ESI
8
5 5.8, (25.8) / IC,ESI –, (11.1) / IC, ESI –
5.1, (9.5) / IC,
ESI –
5.8,(–) / IC,
ESI
7 6.6, (5.7) / IC –, (12.1) / IC – 6.2, (5.2) / IC – 5.2, (–) / IC
9
(n = 2) 5
5.5, (2f/22.6) /
MG 5.8 (3.3
f/27.7) / MG – 5.2 (0
e/1.1) /
NSA –
6.6h, (–) /
NSA
9
(n = 6) 5 6.3, (2.9) / MG 5.7, (3.4) / MG –
5.2 (0e/0.9) /
NSA –
6.8h, (–) /
NSA
9
(n = 9) 5 6.0, (7.7) / IC 6.1, (3.8) / IC –
6.0, (10.6e/–2.0)
/ IC – 5.0, (–) / IC
10
R = Gly
5 5.,5 (8.1) / IC – – – – –
7 4.7, (–) / IC – – – – –
11
R = Gly
5 6.9, (16.5) / IC – – – – –
7 6.0, (–) / IC – – – – –
14
(bis-uracil
analogue)
5 – 4.6, (18.0) / PIC, HB 5.1 / PIC 5.0, (2
e/12.4) /
PIC – –
14
(bis-adenine
analogue)
5 – 5.0, (6.0) / MG 5.3, (1.1) / MG 5.1, (1.5
e/0.3) /
GB – –
Detailed analysis of the DNA and RNA binding parameters
(Table 1) revealed that contrary to the common paradigm about
ethidium bromide derivatives as classical ds-DNA and ds-RNA
intercalators, here presented results show a large variety of
binding modes, very often the same molecule exhibiting more
than one binding mode, depending on the ratio r  =
[compound]/[polynucleotide]. Moreover, there is no set of rules
which will accurately predict the dominant binding site of
newly designed phenanthridine/phenanthridinium analogues.
All aforementioned also hampers the prediction of the fluori-
metric response, which is much more dependent on the binding
mode than on the substituents attached to the chromophore.
However, by the rule of thumb, if phenanthridine substituents at
3,8-positions sterically allow the intercalation into ds-DNA or
ds-RNA, than a binding affinity within the micromolar range
could be expected and the systematic research of Luedtke et al.
[48] allows predictions of the fluorimetric response, while
results of Wagenknecht et al. [88-94] as well as Turro et al. [83-
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Table 1: Binding affinities (log Ks); thermal denaturation effects and proposed binding modes of chosen phenanthridine and phenanthridinium deriva-
tives with natural and synthetic polynucleotides: ds-DNA and ds-RNA. (continued)
16 5.5 – –, (7.7i) / IC, MB 6, (7.4
i ) / IC,
MB
9.3, (34.3 i) / IC,
MB – –
19
5 6.4, (19.6) / TIC 5.4, (10
f/20) / TIC,
MB 6.1 / TIC 6.5, (35.6) / TIC 6.1, (–) / TIC
6.8, (–) /
TIC
7 –, (19.4) / TIC 5.6, (11.3
f/21.6) /
TIC, MB 5.9 / TIC 6.5, (25.5) / TIC 6.9
j, (–) / TIC 6.1, (–) /TIC
20 6.5 – – – 5.9, (19.0k) / IC – 5.5,(–) / IC
aBinding constants calculated from titration data by processing according to the Scatchard equation. br = [compound]/[polynucleotide] = 0.2 if not
stated otherwise. cIC = intercalation; MG = minor groove; NSA = non-specific agglomeration; GB = undefined groove binding; BIC = bis-intercalation;
ESI = electrostatic interaction; HB = hydrogen bonding; PIC = partial intercalation; MB = mixed binding mode; TIC = threading intercalation. dBinding
constants calculated from ethidium bromide displacement experiments [52]. eBiphasic thermal denaturation transitions at pH 5 due to different RNA
forms [62]. fBiphasic thermal denaturation transitions due to bMB, values for both transitions given when possible. gNot possible to calculate due to
systematic deviation of experimental data from best-fitted Scatchard isotherm. hCumulative binding constants for mixed binding mode. ir = [com-
pound]/[polynucleotide] = 0.1. jPolynucleotide is poly(dG–dC)2. kr = [compound]/[polynucleotide] = 0.5.
Table 2: Binding affinities (log Ks) and proposed binding modes of chosen phenanthridine and phenanthridinium derivatives with synthetic polynuc-
leotide ss-RNA.
ligand pH log Ksa / Binding modeb
pA pU pG pC pAc+ (∆Tm)d
PHEN-Mee 57
4.3 / IC
4.8 / IC
<3 / IC
<3 – –
PHEN-H+f 5 5.1 / IC <3 / IC – –
EB [96] 57
3.3 / IC
3.9 / IC
<3 / IC
<3 / IC
3.8 / IC
3.1 / IC
3.3 / IC
<3 / IC
5
R = (CH2)4
6.2 4.2 / IC, NSA 3.7 / IC, NSA 5.3 / IC, NSA – –
5
R = (CH2)6
6.2 3.8 / IC, NSA 4.1 / IC, NSA 5.8 / IC, NSA – –
6
R = (CH2)6
6.2 4.1 / IC, NSA 4.2 / IC, NSA 5.4 / IC, NSA – –
7 6.2 6.3 / BIC 5 / BIC 7.1 / BIC – –
8
5 5.0 / IC 4.5 / IC 6.1 / IC 5.4 / IC –
7 4.6 / IC 4.4 / IC 5.1 / IC 4.5 / IC –
12
(phenanthridinium-adenine) 5 5.3 / IC 4.5 / IC + HB – – –
12
(phenanthridinium-uracil) 5 5.3 / IC >3
g / IC – – –
85] are applicable for the design of DNA charge transfer
processes.
However, these rules do not apply for interactions of phenan-
thridine/phenanthridinium derivatives with significantly more
flexible single stranded (ss-)polynucleotides, for instance
ss-RNA (Table 2). The data about interactions with ss-DNA or
ss-RNA are sparse and deficient, mostly determined for deriva-
tives with substituents aiming toward particular nucleobase
recognition, with very few referent compounds for any final
conclusion about the binding properties of phenanthridine
moiety alone. Nevertheless, binding data obtained for ethidium
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Table 2: Binding affinities (log Ks) and proposed binding modes of chosen phenanthridine and phenanthridinium derivatives with synthetic polynuc-
leotide ss-RNA. (continued)
13
5 – >3 g/ IC – – 5.3, (3) / IC, ESI
7 – >3g / IC – – 4.4 / IC
14
(bis-uracil analogue) 5 – – – – 5.2, (8.0) / PIC, HB
14
(bis-adenine analogue) 5 – – – – 5.1, (0.5) / MG
19
5 – 3.9 / IC 4.7 / IC 2.9 / IC –
7 4.1 / IC 4.4 / IC 4.5 / IC 2.6 / IC –
20 6.5 – – – – 4.5, (6.0) / IC
aTitration data were processed according to the Scatchard equation. bIC = intercalation; MG = minor groove; NSA = non-specific agglomeration; BIC
= bis-intercalation; ESI = electrostatic interaction; HB = hydrogen bonding; PIC = partial intercalation. cpoly A at pH 5 is mostly protonated and forms
ds-polynucleotide [62]. dr = [compound]/[polynucleotide] = 0.2, only for 20 r = 0.5. e8-(Propylamino)-5,6-dimethylphenanthridinium cation [71].
f8-(Propylamino)-6-methylphenanthridine [70]. gEstimated value due to less than 20% of complex formed.
bromide and 8-amino-substituted derivatives with methylated or
protonated heterocyclic N5 (Table 2) show that the phenanthri-
dine/phenanthridinium cation interacts with purine ss-sequences
with affinity approximately one–two orders of magnitude lower
in comparison to ds-DNA or ds-RNA, while interaction with
pyrimidine ss-polynucleotides is even one order of magnitude
lower. This agrees well with the aromatic stacking interactions
between phenanthridine and nucleobase as dominant binding
interaction (most likely intercalation), while differences
between permanent (EB, PHEN-Me) and reversible (PHEN-H+)
positive charge do not play a significant role. Intriguingly, EB
revealed an order of magnitude lower affinity toward poly(A) in
comparison to PHEN-Me and PHEN-H+, which could be attrib-
uted to the steric hindrance of EB at C6 and N5 positions to the
optimal orientation of phenanthridinium within the intercala-
tive binding site between adjacent nucleobases. As expected,
bis-phenanthridine derivatives exhibited higher affinity due to
the bis-intercalative binding mode, and in some cases show a
fluorimetric recognition of a particular ss-polynucleotide (e.g.,
8) due to the fine interplay of binding interactions. Again, very
scarce information about the complex structure did not allow
accurate determination of binding contributions, which would
clarify the observed selectivity.
Although only the current widespread biochemical application
is focused on ethidium bromide/propidium iodide dyes for DNA
dyeing and cell viability tests, results summarised in this review
pointed out the intriguing potential of the phenanthridine/
phenanthridinium system for chemical and biochemical
research. Widely used fluorimetric dyes, such as cyanine
derivatives, are non-fluorescent in the free state but give
tremendous fluorescence emission upon binding to biomacro-
molecular targets. However, many of these dyes show photo-
bleaching, a significant overlap of the absorption and emission
spectrum (minor Stokes shift) and the chemical stability in
stock solution is often declared by the producer to last only
several months. Although the phenanthridine/phenanthridinium
system in principle does not show the ideal combination of non-
emissive form in the free state/very strong emission in the
bound state, it has several advantages over cyanine dyes:
phenanthridine/phenanthridinium fluorescence is characterised
by a large Stokes shift (up to 100 nm) allowing the full use of
absorption maxima as well as easy incorporation in FRET
systems, high resistance to photobleaching and mostly very
high chemical stability. Biomedical use in human medicine was
deterred by the potential carcinogenic and mutagenic properties
of some derivatives (EB and analogues) but this is recently
reassessed due to the evidently innoxious treatment of African
trypanosomiasis in livestock for more than 40 years
(isometamidium chloride hydrochloride and ethidium bromide
[105]), together with recent results on phenanthridine-based
alkaloids and the promising bioactivity of phenanthriplatin [86].
All aforementioned gave the impetus to the phenanthridine/
phenanthridinium system research, which made significant
progress in the study of the most common phenanthridine
substituent positions (3-, 5-, 6-, 8-). Nevertheless, there are still
many promising targets, for instance systematic study of
various substituents attached at rarely used positions
(1-,2-,4-,7-,9-) would be of high interest, especially since
natural phenanthridine alkaloids (Figure 12) are richly substi-
tuted on these positions and very likely owe a lot of biological
activity to particular type of substituent. Several other phenan-
thridine characteristics such as reversible positive charge intro-
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duction by protonation of the heterocyclic nitrogen (N5) were
for the first time applied in designed DNA and RNA interac-
tions, offering new biomedical applications – for instance,
taking advantage of the significantly lower extracellular pH of
many solid tumors [106], to which some antitumor drugs base
their preferential accumulation in tumor tissue due to the
weakly acidic pKa value [107]. Furthermore, phenanthridine
was very scarcely used as a ligand in metal coordination chem-
istry of biomedically oriented research, although heterocyclic
nitrogen (N5) and/or various side-arm substituents offer many
possibilities – as for example, very recently reported recogni-
tion of nucleotides by phenanthridine–lanthanide conjugates
[108]. Finally, there are almost unlimited possibilities of
phenanthridine incorporation into heterogenic fluorescent
probes, taking advantage of the aforesaid phenanthridine spec-
trophotometric characteristics.
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